Khawar Ali Shahzad

Dr. Khawar Ali Shahzad


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MSMavra Saleem
Mavra Saleem
KSKhawar Ali Shahzad
Khawar Ali Shahzad
MMMunazzah Marryum
Munazzah Marryum
SSShekhar Singh
Shekhar Singh
QZQuan Zhou
Quan Zhou
ISImran Ibrahim Shaikh
Imran Ibrahim Shaikh
Exosomes, small extracellular vesicles secreted by cells, have emerged as focal mediators in intercellular communication and therapeutic interventions across diverse biomedical fields. Inflammatory disorders, including inflammatory bowel disease, acute liver injury, lung injury, neuroinflammation, and myocardial infarction, are complex conditions that require innovative therapeutic approaches. This review summarizes recent advances in exosome-based therapies for inflammatory disorders, highlighting their potential as diagnostic biomarkers and therapeutic agents. Exosomes have shown promise in reducing inflammation, promoting tissue repair, and improving functional outcomes in preclinical models of inflammatory disorders. However, further research is needed to overcome the challenges associated with exosome isolation, characterization, and delivery, as well as to fully understand their mechanisms of action. Current limitations and future directions in exosome research underscore the need for enhanced isolation techniques and deeper mechanistic insights to harness exosomes’ full therapeutic potential in clinical applications. Despite these challenges, exosome-based therapies hold great potential for the treatment of inflammatory disorders and may offer a new paradigm for personalized medication.

11 January 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
FTFei Tan
Fei Tan
XLXuran Li
Xuran Li
XLXiao Li
Xiao Li
MXMaoxiang Xu
Maoxiang Xu
KSKhawar Ali Shahzad
Khawar Ali Shahzad
LHLei Hou
Lei Hou
Recent advances in cochlear implantology are exemplified by novel functional strategies such as bimodal electroacoustic stimulation, in which the patient has intact low-frequency hearing and profound high-frequency hearing pre-operatively. Therefore, the synergistic restoration of dysfunctional cochlear hair cells and the protection of hair cells from ototoxic insults have become a persistent target pursued for this hybrid system. In this study, we developed a composite GelMA/PEDOT:PSS conductive hydrogel that is suitable as a coating for the cochlear implant electrode for the potential local delivery of otoregenerative and otoprotective drugs. Various material characterization methods (e.g., 1H NMR spectroscopy, FT-IR, EIS, and SEM), experimental models (e.g., murine cochlear organoid and aminoglycoside-induced ototoxic HEI-OC1 cellular model), and biological analyses (e.g., confocal laser scanning microscopy, real time qPCR, flow cytometry, and bioinformatic sequencing) were used. The results demonstrated decent material properties of the hydrogel, such as mechanical (e.g., high tensile stress and Young’s modulus), electrochemical (e.g., low impedance and high conductivity), biocompatibility (e.g., satisfactory cochlear cell interaction and free of systemic toxicity), and biosafety (e.g., minimal hemolysis and cell death) features. In addition, the CDR medicinal cocktail sustainably released by the hydrogel not only promoted the expansion of the cochlear stem cells but also boosted the trans-differentiation from cochlear supporting cells into hair cells. Furthermore, hydrogel-based drug delivery protected the hair cells from oxidative stress and various forms of programmed cell death (e.g., apoptosis and ferroptosis). Finally, using large-scale sequencing, we enriched a complex network of signaling pathways that are potentially downstream to various metabolic processes and abundant metabolites. In conclusion, we present a conductive hydrogel-based local delivery of bifunctional drug cocktails, thereby serving as a potential solution to intracochlear therapy of bimodal auditory rehabilitation and diseases beyond.

29 May 2013
Verified
Conference Paper
Open access
PDF file
KSKhawar Ali Shahzad
Khawar Ali Shahzad
AKAyesha Khalid
Ayesha Khalid
ZRZoltán Endre Rákossy
Zoltán Endre Rákossy
GPGoutam Paul
Goutam Paul
ACAnupam Chattopadhyay
Anupam Chattopadhyay

29 October 2024 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
ZWZhao Wang
Zhao Wang
KSKhawar Ali Shahzad
Khawar Ali Shahzad
XLXuran Li
Xuran Li
BCBoyu Cai
Boyu Cai
MXMaoxiang Xu
Maoxiang Xu
FTFei Tan
Fei Tan

15 August 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
XWXin Wan
Xin Wan
WPWeiya Pei
Weiya Pei
KSKhawar Ali Shahzad
Khawar Ali Shahzad
LZLei Zhang
Lei Zhang
SSShilong Song
Shilong Song
Chuanlai ShenChuanlai Shen
Chuanlai Shen
In this study, a tolerogenic artificial APC (TaAPC) was developed to directly and selectively modulate myelin-autoreactive CD4+ and CD8+ T cells in the myelin oligodendrocyte glycoprotein (MOG)35–55 peptide–induced experimental autoimmune encephalomyelitis in C57BL/6J mice. Cell-sized polylactic-coglycolic acid microparticles were generated to cocouple target Ags (MOG40–54/H-2Db-Ig dimer, MOG35–55/I-Ab multimer), regulatory molecules (anti-Fas and PD-L1-Fc), and “self-marker” CD47-Fc and encapsulate inhibitory cytokine (TGF-β1). Four infusions of the TaAPCs markedly and durably inhibited the experimental autoimmune encephalomyelitis progression and reduced the local inflammation in CNS tissue. They circulated throughout vasculature into peripheral lymphoid tissues and various organs, but not into brain, with retention of 36 h and exerted direct effects on T cells in vivo and in vitro. Two infusions of the TaAPCs depleted 65–79% of MOG35–55-specific CD4+ and 46–62% of MOG40–54-specific CD8+ T cells in peripheral blood, spleen, and CNS tissues in an Ag-specific manner and regulatory molecule–dependent fashion; induced robust T cell apoptosis; inhibited the activation and proliferation of MOG peptide–reactive T cells; reduced MOG peptide–reactive Th1, Th17, and Tc17 cells; and expanded regulatory T cells. They also inhibited IFN-γ/IL-17A secretion and elevated IL-10/TGF-β1 production in splenocytes but not in CNS tissue. More importantly, the TaAPCs treatment did not obviously suppress the overall immune function of host. To our knowledge, this study provides the first experimental evidence for the capability of TaAPCs to directly modulate autoreactive T cells by surface presentation of multiple ligands and paracrine release of cytokine, thus suggesting a novel Ag-specific immunotherapy for the T cell–mediated autoimmune diseases.

16 January 2024 in Biomedical Materials
Verified
Journal Article
Open access
MYMuhammad Younis
Muhammad Younis
SSSana Shaikh
Sana Shaikh
KSKhawar Ali Shahzad
Khawar Ali Shahzad
FTFei Tan
Fei Tan
ZWZhao Wang
Zhao Wang
MLMushtaq Hussain Lashari
Mushtaq Hussain Lashari
Glioblastoma (GBM) remains a challenging malignancy due to its aggressive nature and the lack of efficacious therapeutic interventions. Nanotechnology-based approaches exhibit promise in GBM treatment; however, the successful translation of these strategies from preclinical models to clinical settings is hindered by inefficient nanoparticle clearance from vital organs. Addressing this concern, we investigated the therapeutic potential of amrubicin (AMR) encapsulated within poly (lactic-co-glycolic acid) nanoparticles (AMR-PLGA-NPs) in combating temozolomide (TMZ) resistant GBM. The study demonstrated that AMR-PLGA-NPs exerted a pronounced inhibitory effect on the cellular viability and migratory capacity of TMZ-resistant GBM cells. Furthermore, these nanoparticles exhibited considerable efficacy in downregulating the PI3K/AKT signaling pathway, thereby inducing apoptosis specifically in TMZ-resistant glioma cells and glioma stem-like cells through the activation of PTEN. Notably, in vivo experimentation revealed the ability of AMR-PLGA-NPs to traverse biological barriers within murine models. Collectively, these findings underscore the potential therapeutic utility of AMR-PLGA-NPs as a versatile nanoplatform for addressing the formidable challenges posed by GBM, particularly in mitigating drug resistance mechanisms. The study substantiates the stability and safety profile of AMR-PLGA-NPs, positioning them as a promising avenue for combating drug resistance in GBM therapeutics.